Biotechnology, and companies like Oryzon Genomics, require a specific type of investor: sophisticated, with long -term vision and risk tolerance. Although the first phases of clinical development are full of uncertainty, the passage to the FASE 3prior to marketing, it represents a huge opportunity for revaluation. Oryzon is about to reach that milestone with the foreseeable authorization by the FDA of the Phase III-2 study protocol Vafidemstat in personality borderline disorder (TLP), which would place us as one of the few Spanish biotechnology in reaching this stage.
In a world that seeks security in traditional sectors, more and more investors explore what is known as «Impact investment»which combines financial return with measurable social or environmental benefits. In this context, biotechnology has been qualified as the «Definitive Impact Investment», having the ability to improve the health and quality of life of millions of people. The development of effective therapies for serious diseases and without adequate treatment – as certain types of cancer or mental disorders – is aligned with the social objectives and gaps that the traditional market has left without attending.
Each euro for biomedical research generates hope for patients and families. This is the Additional From the sector: without these investments, many crucial advances would not exist or take years to arrive. In Oryzon, we develop Epigenetic drugs that respond to that need in an innovative way, addressing market gaps where other companies have not acted.
A clear example of additional and impact is doubtnext to start phase III in TLP, a disease with high suicide rates and a huge health load. Today there is no active pharmaceutical or drug in advanced development for this disorder. Without our initiative, it is likely that patients with TLP had continued without specific treatment for many more years. This bet could lead to First therapy approved for TLP in the worlda transformative impact milestone on mental health. Something similar happens with our program to negative symptoms of schizophrenia, Currently in phase Iib, also without approved therapeutic options.
Another additional example is iadademstatour candidate in Oncology, which offers great impact potential, not only in difficult cancers, but also in anemia of sickle cells (SCD). This disease especially affects regions such as sub -Saharan Africa, the Caribbean, India or Brazil, where access to advanced therapies such as transplants or gene therapies is almost non -existent due to its complexity and cost. Iadademstat, being a treatment oral, simple and epigenetic, It represents an effective, scalable and cost-sustainable solution for health systems with limited resources. Its therapeutic effect on preclinical models of SCD is comparable to that of the approved gene therapies, but with a much more accessible model. With a responsible price model, We could drastically improve access to treatment in highly vulnerable populations.
Oryzon It is located at an exceptional moment. With a robust pipeline, international talent and first level collaborations, we are about to become the first company with a phase III drug for FTA, consolidating our global projection.
For investors seeking diversification, impact and opportunities beyond traditional models, Oryzon represents a unique binomial: Potential for profitability with social commitment. Investing in Oryzon is betting on science, health and progress. In an era where low types force alternatives with added value, biotechnology – and in particular Oryzon— It is emerging as an attractive, responsible and 21st century option